Academic Research
-
Understand the heterogenous nature of disease biology with an enhanced mechanistic understanding of pathology and interventions.
-
Translate your basic research findings in pathophysiology to discover new drug targets.
-
Discover novel disease biomarkers by taking a mechanistic approach to disease biology.
Discovery/Preclinical
-
Validate which disease pathways are interrupted by your therapy. Perhaps more importantly - which are not. Discover new targets to grow your portfolio of assets.
-
Was a drug program a sunk cost for you? Find alternative therapeutic areas or sub-populations where your failed assets may be more effective.
-
Rank and compare ROI for your pipeline’s assets by probability of clinical success and gain leverage in your out licensing agreements.
-
Compare how your drug target compares with your competitors marketed in developing drugs.
Phase I
-
Establish the most safe and effective dose for your expansion cohort/phase. Perform simulations to support your dosing rationale.
-
Predict off-target effects by evaluating your target’s overlap with other physiological pathways.
-
Simulate the effect of modulating multiple pathways simultaneously for your combination therapies.
Solutions at Every Phase of Drug Development
Phase II
-
Understand more about your therapy’s mechanism of action than you ever thought possible by understand the causal mechanisms of efficacy.
-
Identify & validate new biomarkers as well as untangle correlative biomarkers from causal biomarkers.
-
Predict protein concentrations to understand the extent to which protein concentrations are affected upstream/downstream of your target.
Phase III
-
Discover which demographics and patient characteristics are co-variates.
-
Target the right population to reduce the number of patients required to meet efficacy endpoints.
Phase IV/Post-Market
-
Simulate on a single-patient level to optimize dose and regimen.
-
Identify biomarkers to be developed into diagnostics.